All

Results: 7189-7200 of 76596

PR Newswire associated0

ASSAÍ ENDS FIRST QUARTER WITH CONSISTENT CASH GENERATION, LEVERAGE REDUCTION, AND MARKET SHARE GAINS

JPMorganChase Named First-Ever Global Banking Partner of the Olympic Games

Everforth Launches New Era as Rebrand Elevates Technology and Digital Engineering Capabilities at Scale

BlueSnap, Powered by Payroc, Launches Local Acquiring in New Zealand to Boost Approval Rates and Reduce Cross-Border Costs

Mavenir Launches Cloud-Native Packet Core Foundation with Rakuten Mobile in Japan

Datasite® Becomes the First VDR Provider to Connect AI Assistants Directly to Live Deal Content with MCP Server Launch

PR Newswire associated0

NYSE Content Update: Joby Aviation Rings Opening Bell Following NYC Test Flight

PR Newswire associated0

Eightco Holdings (NASDAQ: ORBS) Reports Total Holdings of Approximately $333 Million, Includes OpenAI, Beast Industries, More Than 11,000 ETH and Over 283 Million WLD Tokens

Avner Geva, Cofounder, CEO (left), and Avi Eftel, Cofounder, CTO (right)

Vensica Medical Receives FDA IND Clearance to Initiate Phase 2 Study of ViXe, Its Needle-Free Xeomin® Delivery System for Overactive Bladder

World's First Recombinant Botulinum Toxin Type A New Drug Received Marketing Approval in China: a Technological Revolution pioneered by Claruvis Pharmaceutical

The CTIONCOTEST™ platform by CTIBIOTECH is an innovative 3D bioprinting technology that revolutionizes preclinical cancer research . It provides an automated, industrial-scale process to produce high-throughput, patient-specific human "microtumors" directly from primary tumor cells . Designed to tackle the 95% clinical failure rate of new cancer drugs, it faithfully replicates the complex tumor microenvironment, including critical hypoxic and necrotic zones . Targeting high-mortality breast, colon, and pancreatic cancers, the platform features three complexity levels: standard (cancer cells), intermediate (+fibroblasts), and advanced (+immune/endothelial cells) . A key breakthrough is its record cellular viability of 128 days, enabling unprecedented long-term studies on drug resistance and metastasis . Ultimately, CTIONCOTEST delivers a highly predictive, 100% human-derived ethical alternative to animal testing.

Printing the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care

Workhuman Launches Future Leaders™: Redefining How Organizations Identify and Elevate Internal Leadership Talent